CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

842 results.
Study Number Lead Group Study Title CIRB Study Status
9673 ETCTN PART A: A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal PART B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal Adult CIRB - Early Phase Emphasis Available to Open
10334 ETCTN BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) who are Ineligible or who Refuse Intensive Chemotherapy Adult CIRB - Early Phase Emphasis Available to Open
842 results.